Ram Malladi is a consultant haematologist based at the Centre for Clinical Haematology, who works closely with Professor Charlie Craddock and Professor Paul Moss, focussing on clinical treatment of haematological malignancies, key approaches being being Stem Cell Transplantation, novel chemotherapy regimens, and donor vaccination.
Senior Clinical Lecturer, University of Birmingham
Honorary Consultant Haematologist, University Hospitals Birmingham
Background and Research focus
Following an undergraduate medical degree in Cambridge, Ram received his medical training at King’s College London, and following qualification, went on to do specialist training in haematology at Oxford. He then completed doctoral research at the Weatherall Institute for Molecular Medicine in Oxford in 2010, before being appointed to a Senior Clinical Lectureship at the University of Birmingham in 2010, with an Honorary Consultant role in Haematology at University Hospitals Birmingham.
Since his recruitment to Birmingham, Ram has developed a strong translational haematology programme, supported by close collaborations with Professor Craddock and Professor Moss. His research is centred on Stem Cell Transplantation, and he has a particular interest in immune reconstitution post allogeneic stem cell transplant and how this influences Graft-versus-Host Disease (GvHD) and Graft-versus-Leukaemia (GvL). An LLR-funded Programme with Professor Moss aims to understand mechanisms of GvL, with the aim of specifically boosting such responses in patients. One current focus is on understanding the role of NKG2D/ligand interactions in GvL responses. A second area has been the alloreactive immune response to minor histocompatibility (mHag) peptides on haematopoietic tissue, which is thought to underlie GvL. Ram is working with Professor Moss to boost this response through an LLR-funded vaccination programme targeted at SCT donors to boost mHag-specific immunity prior to transplantation. In parallel with these studies, Ram is collaborating with Professsor Moss on GvHD on understanding and ameliorating GvHD responses. The role of chemokines in guiding alloreactive T cell populations to specific tissues is of major interest, with CXCL10 strongly implicated in acute and chronic GVHD. In this area, Ram holds funding with Professor Moss via an MRC Experimental Medicine Grand Challenge Grant that focuses on suppression of GvHD responses via CXCL10 blockade. As an alternative route to control of GvHD, Ram has won LLR support for a clinical study of azacitidine in the post-transplant setting as a mechanism to increase expansion of T regulatory cells.
Haematological malignancies; lymphoma; stem cell transplantation; graft-versus-host disease (GvHD); graft-versus-leukaemia (GvL); clinical trials.
In addition to his clinical research, Ram is also a trustee of the Cure Leukaemia charity.
Loke J, Ward J, Mahendra P, Chaganti S, Malladi R. Outcomes of EAM conditioned autologous haematopoietic SCT for lymphoma. A matched pairs retrospective single-centre study analysis. Bone Marrow Transplant. 2013 Nov;48(11):1486-7.
Croudace JE, Inman CF, Abbotts BE, Nagra S, Nunnick J, Mahendra P, Craddock C, Malladi R, Moss PA. Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD. Blood. 2012 Nov 15;120(20):4246-55.
Medd P, Nagra S, Hollyman D, Craddock C, Malladi R. Cryopreservation of allogeneic PBSC from related and unrelated donors is associated with delayed platelet engraftment but has no impact on survival. Bone Marrow Transplant. 2013 Feb;48(2):243-8.
Goodyear OC, Dennis M, Jilani NY, Loke J, Siddique S, Ryan G, Nunnick J, Khanum R, Raghavan M, Cook M, Snowden JA, Griffiths M, Russell N, Yin J, Crawley C, Cook G, Vyas P, Moss P, Malladi R, Craddock CF. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012 Apr 5;119(14):3361-9.
Medd P, Monk I, Danby R, Malladi R, Clifford R, Ellis A, Roberts D, Hatton C, Vyas P, Littlewood T, Peniket A. Methotrexate dose delivery is more important than ciclosporin level in graft-versus-host disease prophylaxis following T-replete reduced-intensity sibling allogeneic stem cell transplant. Int J Hematol. 2011 Sep;94(3):266-78.
Carpenter L, Malladi R, Yang CT, French A, Pilkington KJ, Forsey RW, Sloane-Stanley J, Silk KM, Davies TJ, Fairchild PJ, Enver T, Watt SM. Human induced pluripotent stem cells are capable of B-cell lymphopoiesis. Blood. 2011 Apr 14;117(15):4008-11.
Medd P, Littlewood S, Danby R, Malladi R, Clifford R, Wareham D, Jeffery K, Ferry B, Roberts D, Peniket A, Littlewood T. Paraproteinaemia after allo-SCT, association with alemtuzumab-based conditioning and CMV reactivation. Bone Marrow Transplant. 2011 Jul;46(7):993-9.
Malladi RK, Peniket AJ, Littlewood TJ, Towlson KE, Pearce R, Yin J, Cavenagh JD, Craddock C, Orchard KH, Olavarria E, McQuaker G, Collin M, Marks DI; British Society of Blood and Marrow Transplantation. Alemtuzumab markedly reduces chronic GVHD without affecting overall survival in reduced-intensity conditioning sibling allo-SCT for adults with AML. Bone Marrow Transplant. 2009 May;43(9):709-15.
Littlewood T, Malladi R, Peniket A. No more transplantation in CML? Blood. 2007 Dec 15;110(13):4618; author reply 4618-9.
Malladi RK, Peniket AJ, Norton AE, Campbell AJ, Collins GP, Samol J, Eagleton H, Miller E, Morgenstern G, Jones J, Keen-Mcguire A, Barnardo M, Littlewood TJ. Favourable outcome for patients with myeloid disorders treated with fludarabine-melphalan reduced-intensity conditioning and allogeneic bone marrow stem cell transplantation without the use of T-lymphocyte-depleting antibodies. Eur J Haematol. 2004 Aug;73(2):85-92.